

INSTITUTIONAL RESEARCH Specialty Pharma UPDATE REPORT

Member FINRA/SIPC

Toll-Free: 866-928-0928 • www.DawsonJames.com • 101 North Federal Highway - Suite 600 • Boca Raton, FL 33432

Citius Pharmaceuticals (NASDAQ/CTXR)

BUY: Halo-Lido: A Meaningful Reduction in Symptom Severity -Hemorrhoids – Not Factored into our Model.

The high dose formulation of CITI-002, a lidocaine and halobetasol propionate combination formulation; aka Halo-Lido, provided a meaningful reduction in symptom severity, as reported by patients, when compared to individual components alone. Moreover, there were no reported significant adverse events and CITI-002 was well tolerated by patients in the study. Citius intends to schedule an end of Phase 2 meeting with the FDA to begin planning the next steps in the regulatory and clinical development program for CITI-002.

Investment Highlights

Citius announced results from the company's Phase 2B clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoid symptoms. This trial was designed to assess the efficacy of the combination product, select the appropriate dose and endpoints for a Phase 3 trial and to validate the PRO.

- The high dose formulation provided a meaningful reduction in symptom severity, as reported by patients, when compared to individual components alone. Moreover, there were no reported significant adverse events and CITI-002 was well tolerated by patients in the study. Citius intends to schedule an end of Phase 2 meeting with the FDA to begin planning the next steps in the regulatory and clinical development program for CITI-002.
- Treatment effect on hemorrhoidal symptoms was analyzed using the MCT. At the end of the 7-day treatment period, **42% of the patients in the high dose CITI-002 (CITI-002H) group reached MCT** compared to patients treated with high dose halobetasol alone (29%) or patients treated with lidocaine alone (21%). Moreover, proportionally more patients in the CITI-002H cohort reported meaningful and statistically significant improvement as compared to patients treated with lidocaine alone (CMH test, p = 0.035).
- The clinical treatment efficacy outcomes were assessed during 7-day treatment and 7-day follow-up periods using an analysis of covariance, which analyzed changes from baseline. Substantial improvements were seen across all active treatment groups. Although no statistical significance was determined in the changes between the comparison groups, directionally the data signaled that the combination products provided faster relief compared to individual monads, and the relief persisted after completing treatment.

Valuation. We use a 30% risk rate in our free cash flow to the Firm (FCFF), our discounted EPS (dEPS), and sum-of-the-parts (SOP) models on top of a 15% risk rate in our therapeutic models for both products. We equal weight and average these metrics and then round to the nearest whole number to derive our \$8.00 price target.

Risk Factors: These include Clinical Risk, Partnership Risk, Financial Risk, Regulatory Risk, and Legal and Commercial Risks.

June 21, 2023

Jason Kolbert

Managing Director & Senior Analyst jkolbert@dawsonjames.com






Exhibit 1. Income Statement

Mno-Lok, U.S. ST & LT CVC Revenues - CTCL Revenues - Expenses Cost of goods sold COGS % of Revenue Research and development 8,596 8, RAD % of Revenue G&A 6,285 8, SG&A % of Revenue	20A 2021A - - - - 813 12,241	-	1Q23A - - - -	2Q23A - - -	3Q23E - - -	4Q23E - -	2023E	2024E 105,236 79,937	2025E 214,702 114,162	2026E 328,526 133,093	2027E 446,839 135,768	2028E 569,775 138,497	2029E 581,228 141,281	2030E 592,910 144,121	2031E 604,828 147,018	2032E 616,985 149,973	2033E 629,386 152,987
CTCL Revenues - Expenses - Cost of goods sold - COCS % of Revenue - R&D % of Revenue 8,596 R&D % of Revenue 6,285 SG&A 6,285 Stock based comp. G & A 715 Total expenses 27,540 Oper. Inc. (Loss) (27,540)	- 	-	-	-	-	-			, -		.,	, .	, .				
Expenses - Cost of goods sold - COCS % of Revenue - R&D % of Revenue - G&A 6,285 SG&A % of Revenue - Stock based comp. G & A 715 Total expenses 27,540 Oper. Inc. (Loss) (27,540)		· .	-		-			79,937	114,162	133,093	135,768	138,497	141,281	144,121	147,018	149,973	152,987
Expenses Cost of goods sold COS % of Revenue COGS % of Revenue 8,596 8, R&D % of Revenue 6,285 8, G&A 6,285 8, Stock based comp. G & A 715 10 Total expenses 27,540 17, Oper. Inc. (Loss) (27,540) (17,		· .	-	-	-	-											
Expenses Cost of goods sold COGS % of Revenue Research and development R&D % of Revenue 6,285 G&A 6,285 Stock based comp. G & A 715 Total expenses 27,540 Oper. Inc. (Loss) (27,540)		· .	-	-	-												
Cost of goods sold - COGS % of Revenue 8,596 Research and development 8,596 R&D % of Revenue 6,285 G&A 6,285 Stock based comp. G & A 715 Total expenses 27,540 Oper. Inc. (Loss) (27,540)			-				-	185,173	328,863	461,619	582,607	708,272	722,509	737,031	751,845	766,957	782,373
COGS % of Revenue 8,596 8, Rsearch and development 8,596 8, R&D % of Revenue 6,285 8, SG&A 6,285 8, Stock based comp. G & A 715 3 Total expenses 27,540 17, Oper. Inc. (Loss) (27,540) (17,			-					_								_	
Research and development 8,596 8, R&D % of Revenue 6,285 8, G&A 6,285 8, SG&A % of Revenue 715 7 Stock based comp. G & A 715 7 Total expenses 27,540 17, Oper. Inc. (Loss) (27,540) (17,	813 12,241			-	-	1	-	27,776	49,330	69,243	87,391	106,241	108,376	110,555	112,777	115,044	117,356
R&D % of Revenue 6,285 G&A 6,285 Stock based comp. G & A 715 Total expenses 27,540 Oper. Inc. (Loss) (27,540)	813 12,241		15%	15%	15%	15%		15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
G&A 6,285 8/ SG&A % of Revenue 715 715 Stock based comp. G & A 715 7 Total expenses 27,540 17, Oper. Inc. (Loss) (27,540) (17,		17,655	3,446	4,727	3,500	2,328	14,000	14,280	14,566	14,857	15,154	15,457	15,766	16,082	16,403	16,731	17,066
SG&A % of Revenue 715 Stock based comp. G & A 715 Total expenses 27,540 Oper. Inc. (Loss) (27,540)																	
Stock based comp. G & A 715 Total expenses 27,540 17, 0per. Inc. (Loss) (27,540) (17, 17,	095 9,836	11,755	2,603	4,793	2,997	1,596	11,990	18,000	18,000	18,000	18,000	18,000	18,000	18,000	18,000	18,000	18,000
Total expenses 27,540 17, Oper. Inc. (Loss) (27,540) (17,																	
Oper. Inc. (Loss) (27,540) (17,	803 1,455	3,906	1,201	1,166	1,166	1,166	1,166	1,166	1,166	1,166	1,166	1,166	1,166	1,166	1,166	1,166	1,166
	711 23,532	33,317	7,250	10,685	7,663	5,089	27,155	61,222	83,061	103,265	121,711	140,864	143,308	145,802	148,346	150,941	153,588
Interest Income 53	711) (23,532)	(33,317)	(7,250)	(10,685)	(7,663)	(5,089)	(27,155)	123,951	245,803	358,353	460,896	567,409	579,200	591,229	603,500	616,017	628,786
	68 262	251	215	303	303	303	303	303	303	303	303	303	303	303	303	303	303
Gain (loss) on revaluation of derivative warrant liability	110 216		3,586		-	-	-	-	-	-	-	-		-	-	-	-
Interest Expense (16)	(16) -		-														
Pre-tax income (27,503) (17,	548) (23,055)	(33,641)	(3,450)	(10,382)	(7,360)	(4,786)	(26,852)	124,255	246,106	358,657	461,200	567,712	579,504	591,532	603,803	616,320	629,089
Pretax Margin																	
income rax benefit (i revision manany	- 1,451	-					-						-				
Income Tax Expense			144	144				12,167	36,528	71,214	114,653	169,538	173,075	176,684	180,365	184,120	187,951
	0% 5%		0%	0%	0%	0%	0%	10%	15%	20%	25%	30%	30%	30%	30%	30%	30%
	976) (42,834)			(10,526)	(7,360)	(4,786)	(26,852)	112,088	209,578	287,443	346,546	398,175	406,429	414,849	423,438	432,200	441,138
	0.84) (0.46)		(0.02)	(0.07)	(0.04)	(0.03)	(0.16)	0.73	1.11	1.39	1.57	1.72	1.70 1.70	1.68	1.66	1.64 1.64	1.62 1.62
Non GAAP EPS (dil) (1.39) (0 Wqtd Avg Shrs (Bas) - '000s 20,162 36,	0.84) (0.23)	(0.23) 146,066	(0.02) 146,211	(0.06) 146.252	(0.04) 158,898	(0.03) 159,057	(0.15) 152.605	0.73 159,455	1.11 160,094	1.39 160,735	1.57 161,379	1.72 162.026	1.70 162,675	1.68 163,326	1.66 163,981	1.64 164,638	1.62 165,297
Watd Avg Shrs (Bas) - 000s 20,162 36, Watd Avg Shrs (Dil) - 000s 20,162 36,	071 108.599	146,066	146,211	146,252	158,898	159,057	152,605	159,455	160,094	160,735	195,555	201,481	207.586	213.876	220.356	227.033	233,913

Source: Dawson James estimates, company reports



Risk Analysis

In addition to the typical risks associated with development-stage specialty pharmaceutical companies, potential risks specific to Citius Pharmaceuticals, Inc. are as follows:

Partnership risk. Citius Pharmaceuticals, Inc. is in discussions with possible partners today, but there can be no assurances that the Company will be able to secure a favorable partnership.

Commercial risk. There are no assurances that the Company will be able to achieve significant market share and become profitable.

Clinical and regulatory risk. Lead products have to complete clinical trials. Trials may not produce results sufficient for regulatory approval.

Financial risk. The Company may need to raise capital in the marketplace, and there can be no assurances that the Company will be able to successfully raise capital and or do so at favorable terms.

Liquidity Risk. The stock is thinly traded. We note that management owns a significant percentage of the Company.

Legal and intellectual property risk. The Company may have to defend its patents and technical know-how, and there can be no assurances that the patents will not be infringed or will be held as valid if challenged, and or that the Company may infringe on third parties' patents.

Companies mentioned in this report

Important Disclosures:



Price target and rating changes over the past three years:

Initiation – Buy – 12/15/2017 – Price Target \$10.00
Update – Buy – 7/6/2018 – Price Target \$10.00
Transfer – Buy – 9/6/2019 – Price Target \$7.00
Update – Buy – 10/7/2019 – Price Target \$7.00
Update – Buy – 12/19/2019 – Price Target \$7.00
Update – Buy – 2/4/2020 – Price Target \$7.00
Update – Buy – 2/25/2020 – Price Target \$7.00
Update – Buy – 5/26/2020 – Price Target \$7.00
Update – Buy – 9/28/2020 – Price Target \$7.00
Update – Buy – 9/29/2020 – Price Target \$7.00
Update – Buy – 11/30/2020 – Price Target \$7.00
Update – Buy – 1/26/2021 – Price Target \$6.00
Price Target Change – Buy – 2/18/2021 – Price Target \$8.00
Update – Buy – 3/10/2021 – Price Target \$8.00
Update – Buy – 5/21/2021 – Price Target \$8.00



Update - Buy - 6/9/2021 - Price Target \$8.00 Update - Buy - 7/1/2021 - Price Target \$8.00 Price Target Change – Buy – 9/9/2021 – Price Target \$10.00 Update – Buy – 12/6/2021 – Price Target \$10.00 Update - Buy - 2/11/2022 - Price Target \$10.00 Update - Buy - 2/15/2022 - Price Target \$10.00 Update – Buy – 4/6/2022 – Price Target \$10.00 Update - Buy - 4/18/2022 - Price Target \$10.00 Update – Buy – 4/26/2022 – Price Target \$10.00 Update – Buy – 5/5/2022 – Price Target \$10.00 Update - Buy - 5/13/2022 - Price Target \$10.00 Update - Buy - 5/25/2022 - Price Target \$10.00 Update - Buy - 7/12/2022 - Price Target \$10.00 Update - Buy - 8/15/2022 - Price Target \$10.00 Update - Buy - 9/28/2022 - Price Target \$10.00 Update - Buy - 12/6/2022 - Price Target \$10.00 Update - Buy - 12/23/2022 - Price Target \$10.00 Update - Buy - 2/14/2023 - Price Target \$10.00 Update - Buy - 3/31/2023 - Price Target \$10.00 Update - Buy - 4/25/2023 - Price Target \$10.00 Update - Buy - 5/4/2023 - Price Target Change \$10.00 to \$8.00 Update - Buy - 5/18/2023 - Price Target \$8.00 Update - Buy - 6/21/2023 - Price Target \$8.00

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the Company (s) in this report and may increase or decrease holdings in the future. As of May 25, 2023, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject Company (s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the Company (s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the "VALUATION" and "RISK ANALYSIS" sections of this report.

The securities of the Company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request. **Rating Definitions:**



- 1) **Buy**: The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral**: The analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell**: The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of	25-IVIAY-23			
	Company		Investment	
	Coverage		Banking	
				% of
Ratings Distribution	# of Companies	% of Total	# of Companies	Totals
Market Outperform (Buy)	26	72%	2	6%
Market Perform (Neutral)	10	28%	1	3%
Market Underperform (Sell)	0	0%	0	0%
Total	36	100%	3	9%

Current as of 25-May-23

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.